Point-of-care HIV testing
|
|
|
- Scott Nash
- 6 years ago
- Views:
Transcription
1 Point-of-care HIV testing Joanne Stekler, MD MPH Associate Professor University of Washington December 5, 2016 Disclaimer: The findings and conclusions in this presentation are those of the author(s) and do not necessarily represent the views of the Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention.
2
3 Objectives 1. Learn about advantages and disadvantages of point-of-care HIV tests. 2. Learn about issues re: point-of-care HIV testing in context of pre-exposure prophylaxis (PrEP).
4 Fiebig et al. AIDS, 2003 Sep 5; 17(13):
5 HIV test Method Window 1 st gen EIA (Ab) viral lysate ~ 4-6 wks 2 nd gen EIA (Ab) purified HIV-1/2 Ag or recombinant 3 rd gen EIA (Ab) synthetic peptide, 4 th gen assay (Ab plus p24 Ag) Pooled HIV RNA (HIV NAAT) antigen sandwich detects IgM detects either antibody or p24 Ag ~ 3-4 wks ~ 2-3 wks ~ 2 wks <1-2 wks Adapted from Stekler CID 2007
6 Oraquick Advance DPP HIV 1/2 Chembio Sure Check INSTI HIV 1/2 Chembio Stat Pak Uni-Gold Recombigen Slide courtesy of Bernie Branson
7 Determine HIV-1/2 Ag/Ab Combo (Alere)
8 Advantages Patient Preference? Potential Avoidance of Blood Draw/ Biohazard More Persons Receive Results Disadvantages Potential for Preliminary False-Positive Results Longer window period
9 # HIV-positive Cumulative HIVpositive Cumulative Sensitivity OraQuick 314 (2.0%) % EIA 40 (0.3%) % NAAT 52 (0.3%) %
10 APTIMA (-26) Architect Combo (-20) Bio-Rad Combo (-19) Determine Combo (-15) GS 1/2+O (-12) INSTI (-9) Multi-Spot (-7) Reveal G3 (-6) COMPLETE HIV-1/2 (-5) HIV-1/2 STAT-PAK (-5) OraQuick (-1) Unigold (-2) WB positive Vironostka (+) Modified from Masciotra et al, J Clin Virol 2011 and Owen et al, J Clin Micro 2008 Slide courtesy of Bernie Branson 5 0 Days before WB positive
11 POC tests (each test on separate fingerstick) OraQuick (oral fluids and fingerstick) Uni-Gold or INSTI Determine HIV-1/2 Ag/Ab EIA PHSKC: 3 rd gen Genetic Systems HIV-1/HIV-2 Plus O EIA PIC: 4 th gen Abbott ARCHITECT HIV Ag/Ab Combo assay NAAT PHSKC: 27-specimen master pools (3x3x3 matrix) Abbott RealTime HIV-1 RNA assay McNemar s exact tests compared numbers of cases detected
12 STD Clinic & Gay City PIC Total n=3404 n=34 n=3438 Concordant Positive POC Tests 82 (77%) Discordant POC Antibody Tests 10 (9%) All POC Negative/EIA Positive 6 (6%) 0 6 Acute (EIA Neg / NAAT Pos) 9 (8%) 2 11 Total HIV Positive 107 (3.1%) Stekler, J Clin Virol 2016; Stekler, J Clin Virol 2013; O Neal, JAIDS 2012
13
14 # tested # AHI detected Taegtmeyer PLoSOne 2011 UK 953 none Rosenberg JID 2012 Malawi 838 0/8 Kilembe PLoSOne 2012 Rwanda, Zambia 1/52 Conway PLoSOne 2014 Australia /9 Duong J Clin Microbiol 2014 Swaziland 18,172 0/13 Stekler J Clin Virol 2016 US /11 >26,591 2/93
15 N tested Specificity (95% CI) OraQuick (oral fluid) 2109/2112 = 99.86% ( ) OraQuick (fingerstick) 2107/2107 = 100% ( ) Uni-Gold 1561/1561 = 100% ( ) INSTI 543/544 = 99.82% ( ) Determine Combo 1468/1483 = 98.99% ( ) GS HIV-1/HIV-2 Plus O antibody (EIA) 2091/2095 = 99.81% ( ) Stekler, J Clin Virol, 2016 Meta-analysis Overall pooled specificity (plasma, serum, WB) 99.1% ( ) Smallwood et al. PLoS One (2)
16 Point-of-care HIV tests are not all the same. Oral fluid is significantly inferior and should be the specimen type of last resort. Determine Combo, although a 4 th generation POC test, is not equivalent to lab-based testing when looking for AHI. But it still may pick up a case or two. Other factors may impact device choice Cost Time (1 minute v minutes) Blood volume (5 v 50µL)
17 When starting PrEP, use the test with shortest window period available. Do not use oral fluid tests. (starting PrEP during AHI resistance) Do not ask people to remain abstinent/use condoms while waiting out the window period. Screen for symptoms of AHI If symptoms and recent exposure delay PrEP start *Almost all* symptomatic AHI will test pos on lab 4 th gen But. There is a 2 nd window period. PrEP may lead to delayed seroconversion and falsenegative tests, particularly with oral fluid tests.
18 HIV testing in PrEP Analysis of False Negative HIV Tests Based on Oral Fluid in 3 Clinical Trials (Curlin, CROI 2016, #635) false negative OQOF results among 28% of 290 seroconverters. - Median OQOF reactivity delay time was 98 (range ) days. The Effect of Oral Pre-exposure Prophylaxis on the Progression of HIV-1 Seroconversion (Donnell, HIVR4P 2016, #OA03.01) seroconversions - Slight delay in Fiebig progression and delayed detection in some using fingerstick HIV tests
High Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEP Joanne Stekler, MD MPH Associate Professor, Department of Medicine University of Washington Inter-Center for AIDS Research Antiretrovirals
1 st and 2 nd Generation EIA
HIV Diagnostic Tests Bernard M. Branson, M.D. Associate D irector for Laboratory D iagnostics Division of HIV/AIDS Prevention Centers for D isease Control & Prevention The views expressed in this presentation
The Latest in HIV Tests: What Do the Results Mean?
The Latest in HIV Tests: What Do the Results Mean? Bernard M. Branson MD Principal Consultant, Scientific Affairs LLC Atlanta, Georgia Objectives At the end of this workshop, participants will be able
HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch
HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd
Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*
Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
HIV Testing Technology and the Latest Algorithm
HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with
Joanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV Testing Joanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program Presentation prepared
Routine HIV Testing Community of Practice Session #2
Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing
Diagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
The Evolving Landscape of HIV Prevention and Diagnosis
The Evolving Landscape of HIV Prevention and Diagnosis Jenny R. McFarlane Texas Department of State Health Services HIV/STD/TB/Viral Hepatitis Unit Is it okay if we just talk? NHAS: A Call to ACT Reduce
HIV/HCV Screening in 2015: Where Are We Now? Bernard M. Branson, M.D.
HIV/HCV Screening in 2015: Where Are We Now? Bernard M. Branson, M.D. Disclosures Dr. Branson has no financial interests to disclose. Terminology Diagnostic testing: performing a test based on clinical
A Summary of Clinical Evidence
A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table
Overview of HIV Testing Practices and Technology
Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease
New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention
New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection
Failure of the Alere Determine 4th Generation HIV POC test to Detect an Acute Case of HIV-1 Infection
Failure of the Alere Determine 4th Generation HIV POC test to Detect an Acute Case of HIV-1 Infection Carol Loring, MS Rachel Gridley Fengxiang Gao, MD, MPH NH Public Health Laboratories Concord, NH Conflicts
List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation
Alere (honoraria) List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation testing algorithm Interpret challenging
Rapid testing algorithm performance in a low prevalence environment: NJ
Rapid testing algorithm performance in a low prevalence environment: NJ 2015-8 Alere Determine HIV-1/2 Ag/Ab Combo Trinity Biotech Uni-Gold HIV1/2 Recombigen Eugene G. Martin, PhD HIV Diagnostics Conference
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010
Currently Approved CBER Device Premarket Applications (PMAs) As of Nov 10, 2014 Sorted by Applicant Name BP090080-0 BP060002-0 BP120037-0 BP090022-0 BP090032-0 BP040046-0 BP100064-0 BP140120-0 Abbott Laboratories
INTEGRATING HIV AND HCV TESTING
INTEGRATING AND HCV TESTING OVERVIEW Increasingly health departments (HDs) are seeking new strategies to improve the productivity and yield of testing and linkage programs, expand availability of and access
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites. Updated: February 2018 Cicely Richard Office of HIV/AIDS
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites Updated: February 2018 Cicely Richard Office of HIV/AIDS Updated: February 2018 Cicely Richard Office of HIV/AIDS UNIGOLD RECOMBIGEN HIV 1/2 TRAINING
Clinical Education Initiative TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING. Bernard M.
Clinical Education Initiative Support@ceitraining.org TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING Bernard M. Branson, MD 1/23/2018 Testing for HIV and HCV: What s Current and What s Coming
HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)
HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC
How are testing technologies used to diagnose HIV infection?
HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,
New HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES
ISSUES IN BRIEF: MEMBER SURVEY OF HIV ASSAY USE ASSOCIATION OF PUBLIC HEALTH LABORATORIES MARCH 2010 HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES Twenty years ago, the Association of Public Health
HIV testing technologies
HIV testing technologies HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including
Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic
Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic algorithms KP Delaney, M Pentella, B Bennett, and K Landgraf for the CDC/APHL
Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
Rapid HIV Antibody Testing Update
Rapid HIV Antibody Testing Update Devery Howerton, Ph.D. Division of Laboratory Systems Centers for Disease Control and Prevention CLIAC meeting, February 15, 2007 Purpose: Why Rapid HIV Testing? An example
HIV Testing in a High-Incidence Population: Is Antibody Testing Alone Good Enough?
HIV/AIDS MAJOR ARTICLE HIV Testing in a High-Incidence Population: Is Antibody Testing Alone Good Enough? Joanne D. Stekler, 1,3,4 Paul D. Swenson, 2,4 Robert W. Coombs, 1,2,3 Joan Dragavon, 2 Katherine
2018 HIV and HCV Diagnostic Testing Survey
2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will
Objectives. Seven days of separation. Clinical situation a transplant. The Donor COOMBS MD PHD 1. Laboratory Diagnosis & Monitoring of HIV Infection
Laboratory Diagnosis & Monitoring of HIV Infection An Introduction to Diagnostic HIV Testing Robert W Coombs MD, PhD, FRCPC Professor, Departments of Laboratory Medicine & Medicine University of Washington,
HIV Testing: What s New? Kenneth H. Mayer, MD
HIV Testing: What s New? Kenneth H. Mayer, MD CART Symposium, Chennai, India April 28 th, 2018 thefenwayinstitute.org The Status Neutral Continuum HIV Testing RETAINED ON PrEP PRESCRIBED PrEP LINKED TO
Model Performance Evaluation Program (MPEP) HIV Rapid Testing Survey: Report of Sample Shipment Results, September 2009
Use of trade names and commercial sources is for identification only and does not constitute endorsement by the Public Health Service or the U.S. Department of Model Performance Evaluation Program (MPEP)
Bringing excellence to life
Who believes in oral HIV point-of-care tests? A summary of 3 years experience and more than 2000 OraQuick ADVANCE tests N Garrett, J Saunders, K Moir, J Zelin, C Estcourt On behalf of North East London
HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town
HOPE Follow-Up Algorithm: Unusual Cases Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town MTN-025 Testing Algorithm Screening/Enrollment MTN-025 Testing Algorithm
AccuSet HIV-1/2 Performance Panel
OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple
HIV SELF-TESTING AFRICA
UNITAID PSI HIV SELF-TESTING AFRICA Zambart: Interim Results of Clinical Performance Study Alwyn Mwinga Overview of Presentation Study Objectives Clinical Performance study Visual stability study Progress
NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM)
NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM) 30 NOVEMBER 2018, BRUGGE 0 NEW CHALLENGES FOR ACCURATE HIV-1
Defining Recent HIV Infection for TDR Surveillance
Defining Recent HIV Infection for TDR Surveillance Chunfu Yang, DVM, PhD Team Lead of Molecular Diagnostics and Surveillance International Laboratory Branch DGHA, CGH CDC, USA March 19, 2013 Direct Methods:
Arizona State Office of Rural Health Webinar Series
Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere HIV Combo WHO reference number: PQDx 0243-013-00 Alere HIV Combo with product codes 7D2842, 7D2843, 7D2843SET manufactured by Alere
TAP HERE TO SEE THE PRODUCT
TAP HERE TO SEE THE PRODUCT Make every testing opportunity count. Acute infection accounts for 5-20% of all cases of HIV infection among persons seeking testing.1 This acute phase of infection is associated
AccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
New tools for diagnosis and surveillance
New tools for diagnosis and surveillance Beth A Skaggs, PhD Laboratory Advisor, Division of Global HIV/AIDS CDC-Mozambique AIDS MEDICINES AND DIAGNOSTICS (AMDS) ANNUAL STAKEHOLDERS AND PARTNERS MEETING
HIV Guideline Sakchai Dettrairat
HIV Guideline 2016 Sakchai Dettrairat Division of Clinical Immunology Department of Medical Technology Faculty of Associated Medical Sciences Chiang Mai University Appearance of HIV markers in early HIV
Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance
Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance Kristen Mahle, MPH HIV Incidence & Case Surveillance Branch DHAP, NCHHSTP, CDC 2010 Diagnostics Conference March 24, 2010
Screening and Diagnosis of Hepatitis Virus Infections
Screening and Diagnosis of Hepatitis Virus Infections Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor
Diagnostics: Bench to Bedside Pathway
Diagnostics: Bench to Bedside Pathway Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre London School of Hygiene & Tropical Medicine www.idx-dx.org The
UPDATE HIV Coordinators Meeting 2018 NEW JERSEY HOSPITAL ASSOCIATION MAY 10, 2018
HIV Coordinators Meeting 2018 UPDATE - 2018 NEW JERSEY HOSPITAL ASSOCIATION MAY 10, 2018 Rutgers, The State University of New Jersey Eugene G. Martin, Ph.D Professor of Pathology and Laboratory Medicine
Complicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
Adventures in Discordance- HIV Testing
Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody
Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc)
Date: 6 January 2012 Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc) WHO Collaborating Centre for HIV/AIDS Diagnostic and Laboratory Support Department of Clinical Sciences
CAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING
Institute of Medicine (2010) CAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING Workshop on the Capacity of the Healthcare System to Identify and Provide Care for Individuals with HIV/AIDS
2006 HIV Diagnostics Survey
Public Health Laboratory Issues in Brief: 2006 HIV Diagnostics Survey Association of Public Health Laboratories November 2007 Background Nearly 20 years ago, the Association of Public Health Laboratories
The HIV Bridge Algorithm: Linking Point-of-Contact, Laboratory and Patient Care HIV Diagnostic Conference March 24, 2010
The HIV Bridge Algorithm: Linking Point-of-Contact, Laboratory and Patient Care 2010 HIV Diagnostic Conference March 24, 2010 Berry Bennett, MPH Retrovirology Section Chief Florida Bureau of Laboratories
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Immunology 2017 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs
The Journal of Infectious Diseases BRIEF REPORT Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs Constance Delaugerre, 1,4 Guillemette Antoni, 7 Nadia Mahjoub, 1,4 Gilles Pialoux,
HIV testing has significantly improved
HIV testing: an update By Nicola Zetola, MD, and Jeffrey D. Klausner, MD, MPH HIV testing has significantly improved since the first diagnostic test in 1985. Increased understanding of HIV transmission
The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013
The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013 Christopher Bentsen, M.S.,RAC, FRAPS Bio-Rad Laboratories, Redmond,
HIV-1 Seroconversion Panel PRB973
A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians
SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World
MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our
HIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center
HIV Testing Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center The Number of Persons in the US Living with HIV Continues to Increase Over 1 Million people are estimated
HEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection
===========ir ~~!!~~fk li=:='========= Nirav R. Shah, M.D., M.P.H. Commissioner May 16, 2013 HEALTH Sue Kelly Executive Deputy Commissioner Re: Interim Guidelines for Laboratories on the use of a new Diagnostic
Extragenital Gonorrhea and Chlamydia among MSM
Extragenital Gonorrhea and Chlamydia among MSM Laura Quilter, MD Infectious Disease and STD PTC Fellow University of Washington Division of Allergy and Infectious Diseases 3/28/2016 uwptc@uw.edu uwptc.org
PrEP 201: Beyond the Basics
NORTHWEST AIDS EDUCATION AND TRAINING CENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington February 19, 2015 Disclosures and Disclaimers I
Robert Wood Johnson Medical School NJ HIV: Status Update
Robert Wood Johnson Medical School NJ HIV: Status Update Eugene G. Martin, Ph.D Professor of Pathology and Laboratory Medicine Co-Director, NJ HIV Rutgers, The State University of New Jersey 1. NJ HIV
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Immunology 2017 MLE-M3 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
HIV Diagnostic Testing
In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk
STARHS/RITA and Misclassification
Optimization and Calibration of Less Sensitive and Avidity Modified Protocols for the Vitros Immunodiagnostic Products Anti-HIV- 1+2 Assay for Detection of Early HIV Infections Sheila M. Keating, Debra
HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx 0159-055-00 OraQuick HIV 1/2 Rapid Antibody Test with product codes 5x4-0010
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx 0159-055-00 OraQuick HIV 1/2 Rapid Antibody Test with product codes 5x4-0010
HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
2017 HIV AND HCV DIAGNOSTICS SURVEY REPORT
207 HIV AND HCV DIAGNOSTICS SURVEY REPORT MARCH 209 Table of Contents Background...3 Methods...3 Workforce...3 HIV Assay Utilization...4 Turnaround Time...6 Testing Volume and Specimen Types...7 Testing
Robert G. Gish MD UC San Diego
Robert G. Gish MD UC San Diego The Pipeline of HIV-Related Point-Of- Care Tests is Growing Viral detection Examples: 2012 2013 2014 2015 2016 2017 CD4 test Examples: 2009 2010 2011 2012 2013 0 2014 Evidence
The author has received speaker honoraria and travel assistance from Bio-Rad, inc.
CVI Accepted Manuscript Posted Online 2 March 2016 Clin. Vaccine Immunol. doi:10.1128/cvi.00053-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 Human Immunodeficiency Virus
Mom Chandara, Msc, NIPH Team
Mom Chandara, Msc, NIPH Team EXTERNAL QUALITY ASSESSMENTS (EQAS) EQA refers to a system in which laboratory results are scrutinized objectively by an outside agency in order to get a general impression
Featured Article. Evaluation of Four Qualitative Third-Generation HIV Antibody Assays and the Fourth-Generation Abbott HIV Ag/Ab Combo Test
Submitted 4.8.11 Accepted 4.8.11 Evaluation of Four Qualitative Third-Generation HIV Antibody Assays and the Fourth-Generation Abbott HIV Ag/Ab Combo Test Frank H. Wians Jr., PhD, MT(ASCP), DABCC, FACB,
Supplementary Online Content
Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.
Introduction to Communicable Disease Surveillance and Investigation in North Carolina
Introduction to Communicable Disease Surveillance and Investigation in North Carolina Human Immunodeficiency Virus Peter A. Leone, MD Medical Director, HIV/STD NC Division of Public Health and Professor
Module 3: Overview of HIV Testing Technologies
Module 3: Overview of HIV Testing Technologies Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with a basic knowledge of HIV testing and how HIV rapid test results
DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS
DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS ISBT TTID WP 17 June 2017 Marion Vermeulen, Karin van den Berg, Genevieve Jacobs, Brian Custer, Ronel Swanevelder, Ute Jentsch,
HIV-1 Seroconversion Panel PRB975
Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,
Evidence on the impact of POC testing for addressing pediatric HIV
Evidence on the impact of POC testing for addressing pediatric HIV J E N N I F E R C O H N, E G PA F J I L I A N A. S A C K S, C H A I AIDS2018 Satellite Session: Key Considerations and Implementation
PrEP: Preexposure Prophylaxis to prevent HIV Lisa Pietrusza, BSN, RN FNP-DNP student, University of Pittsburgh Nov. 3, 2017.
PrEP: Preexposure Prophylaxis to prevent HIV Lisa Pietrusza, BSN, RN FNP-DNP student, University of Pittsburgh Nov. 3, 2017 Disclosures The views expressed heroine do not necessarily reflect the official
Which of the Two Make the Best Soul Mate: An Autoantibody, Antibody or Antigen? Maria Crisostomo, September 28, 2018
Which of the Two Make the Best Soul Mate: An Autoantibody, Antibody or Antigen? Maria Crisostomo, September 28, 2018 Disclosure Employee and stock holder of Bio-Rad Laboratories 2 Outline At the completion
OR: Steps you can take in the clinic to prevent HIV infections
Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute
The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?
Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection
ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer
ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer Questionnaire on NAT Screening of Blood Donations for an International Forum on 10 years of NAT Screening
Equity Research. Chembio Diagnostics Inc. (CEMI-OTC) CEMI: Solid Q2. Beats on Revenue and EPS. OUTLOOK SUMMARY DATA ZACKS ESTIMATES
July 30, 2010 Equity Research Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 111 North Canal Street, Chicago, IL 60606 Chembio Diagnostics Inc. (CEMI-OTC) CEMI: Solid Q2. Beats on Revenue and EPS.
ANTIBODY SCREENING by Uni-Gold Recombigen HIV
ANTI-HIV SPECIMEN 1 REQUIREMENTS ANTIBODY SCREENING by Uni-Gold Recombigen HIV PRINCIPLE: The Uni-Gold Recombigen HIV was designed as a rapid immunoassay and is intended to detect antibodies to HIV- 1
One week of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection
One week of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection A Elgalib, A Skingsley, O Dosekun, S Alexander, CYW Tong, JA White. Ali Elgalib Consultant in GUM/HIV
Utility of Virological Assays at the DAA Era
Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
T pallidum. Table of contents
An assessment of Point of Care Tests for Hepatitis B, Hepatitis C, HIV and Syphilis for use in an Operational Environment to Provide Emergency Transfusion Support Microbiological Diagnostics Assessment
WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: Alere Determine HIV-1/2 Number: PQDx Abstract
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: Alere Determine HIV-1/2 Number: PQDx 0033-013-00 Abstract The Alere Determine HIV-1/2 with product codes 1 7D2342, 7D2343 and 7D2243